T-cells play an important role in in vivo tumor rejection in many anim
al tumor models and in human melanoma. Many human tumor antigens recog
nized by autologous T-cells have now been identified. These are found
to be nonmutated and mutated peptides derived from various self protei
ns as well as viral proteins. A variety of mechanisms involved in gene
rating these T-cell epitopes on growing cancers have also been identif
ied. However, the role of these identified antigens remains to be eval
uated. Passive or active immunotherapies using these identified tumor
antigens are being conducted in many institutions. The results obtaine
d from these clinical trials may give us better insight into the role
of T-cell responses to each antigen in tumor rejection as well as the
development of new antigen-specific immunotherapies for patients with
cancer.